Diabetic Foot Ulcer Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Diabetic Foot Ulcer Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Diabetic Foot Ulcer Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Diabetic Foot Ulcers Therapeutics market. The report identifies the key trends shaping and driving the global Diabetic Foot Ulcers Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Diabetic Foot Ulcers Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Diabetic Foot Ulcers Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Diabetic Foot Ulcers Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Diabetic Foot Ulcers Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Diabetic Foot Ulcers Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Diabetic Foot Ulcers Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Diabetic Foot Ulcers Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Diabetic Foot Ulcers Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Diabetic Foot Ulcers Therapeutics market landscape? – Identify, understand and capitalize. SHOW LESS READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Diabetic Foot Ulcer Therapeutics - Introduction
2.1 Overview
2.1.1 Diabetic Foot Ulcer Classification Systems
2.2 Epidemiology
2.2.1 Historic Epidemiology (2006-2011)
2.2.2 Forecast Epidemiology (2011-2019)
2.3 Prognosis
2.4 Etiology
2.5 Symptoms
2.6 Diagnosis
2.6.1 History
2.6.2 Neurologic Examination
2.6.3 Vascular Examination
2.6.4 Musculoskeletal Examination
2.6.5 Wound Evaluation
2.6.6 Laboratory Testing and Imaging Studies
2.7 Pathophysiology
2.8 Treatment and Management Pattern
2.8.1 Infection Control
2.8.2 Mechanical Load Relief
2.8.3 Wound Care/Debridement
2.8.4 Blood Glucose Control
2.8.5 Patient Education
2.9 Referral Pathway
2.10 GlobalData Pipeline Report Guidance
3 Diabetic Foot Ulcer Therapeutics - Market Characterization
3.1 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - Global
3.2 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - Global
3.3 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - The US
3.4 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - The US
3.5 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - France
3.6 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - France
3.7 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - Germany
3.8 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - Germany
3.9 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - Italy
3.10 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - Italy
3.11 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - Spain
3.12 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - Spain
3.13 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - The UK
3.14 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - The UK
3.15 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - Japan
3.16 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - Japan
3.17 Drivers and Barriers for the Diabetic Foot Ulcer Therapeutics Market
3.17.1 Drivers of the Diabetic Foot Ulcer Therapeutics Market
3.17.2 Barriers for the Diabetic Foot Ulcer Therapeutics Market
3.18 Opportunity and Unmet Need
3.19 Key Takeaway
4 Diabetic Foot Ulcer Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the Diabetic Foot Ulcer Therapeutics Market
4.4 Anti-infectives
4.4.1 Invanz (ertapenem)
4.4.2 Zosyn (piperacillin/tazobactam)
4.4.3 Zyvox (linezolid)
4.5 Wound-healing Products
4.5.1 Regranex (becaplermin)
4.6 Key Takeaway
5 Diabetic Foot Ulcer Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Diabetic Foot Ulcer Therapeutics - Pipeline Analysis by Phase of Development
5.3.1 Diabetic Foot Ulcer Therapeutics - Phase III Pipeline
5.3.2 Diabetic Foot Ulcer Therapeutics - Phase II Pipeline
5.3.3 Diabetic Foot Ulcer Therapeutics - Phase I Pipeline
5.3.4 Diabetic Foot Ulcer Therapeutics - Preclinical and Discovery Pipeline
5.4 Diabetic Foot Ulcer Therapeutics - Pipeline by Mechanism of Action
5.5 Technology Trends Analytical Framework
5.6 Profiles of Promising Drugs
5.6.1 CVBT-141B (FGF-1)
5.6.2 Fragmin (dalteparin sodium)
5.6.3 Trafermin
5.6.4 Heberprot-P
5.6.5 HO/03/03
5.6.6 CureXcell
5.7 Key Takeaway
6 Diabetic Foot Ulcer Therapeutics - Clinical Trial Mapping
6.1 Clinical Trials by Region and Country
6.2 Clinical Trials by Phase of Clinical Development
6.3 Clinical Trials by Trial Status
6.4 Clinical Trials by Sponsors
6.5 Top Companies Participating in Diabetic Foot Ulcer Therapeutics Clinical Trials
7 Diabetic Foot Ulcer Therapeutics - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
8 Diabetic Foot Ulcer Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Pfizer Inc.
8.2.2 Cardiovascular Biotherapeutics, Inc.
8.2.3 HealOr Ltd.
8.2.4 MacroCure Ltd.
8.2.5 Other Companies in the Pipeline
9 Diabetic Foot Ulcer Therapeutics - Licensing and Partnership Deals
10 Diabetic Foot Ulcer Therapeutics - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Bibliography
10.4 Physicians and Specialists Included in this Study
10.5 Research Methodology
10.5.1 Coverage
10.5.2 Secondary Research
10.5.3 Forecasting
10.5.4 Primary Research
10.5.5 Expert Panel Validation
10.6 Contact Us
10.7 Disclaimer

1.1 List of Tables
Table 1: Diabetic Foot Ulcer - Wagner-Meggitt Classification
Table 2: The University of Texas - Diabetic Wound Classification System
Table 3: Diabetic Foot Ulcer, Global, Prevalence Population, 2006-2011
Table 4: Diabetic Foot Ulcer, Global, Prevalence Population, 2011-2019
Table 5: Diabetic Foot Ulcer - Risk Factors
Table 6: Diabetic Foot Infections - Empirical Antibiotic Regimens
Table 7: Diabetic Foot Infection Therapeutics Market, Global, Revenue ($m), 2006-2011
Table 8: Wound-healing Therapeutics Market, Global, Revenue ($m), 2006-2011
Table 9: Diabetic Foot Infection Therapeutics Market, Global, Forecast ($m), 2011-2019
Table 10: Wound-healing Therapeutics Market, Global, Forecast ($m), 2011-2019
Table 11: Diabetic Foot Infection Therapeutics Market, The US, Revenue ($m), 2006-2011
Table 12: Wound-healing Therapeutics Market, The US, Revenue ($m), 2006-2011
Table 13: Diabetic Foot Infection Therapeutics Market, The US, Forecast ($m), 2011-2019
Table 14: Wound-healing Therapeutics Market, The US, Forecast ($m), 2011-2019
Table 15: Diabetic Foot Infection Therapeutics Market, France, Revenue ($m), 2006-2011
Table 16: Wound-healing Therapeutics Market, France, Revenue ($m), 2006-2011
Table 17: Diabetic Foot Infection Therapeutics Market, France, Forecast ($m), 2011-2019
Table 18: Wound-healing Therapeutics Market, France, Forecast ($m), 2011-2019
Table 19: Diabetic Foot Infection Therapeutics Market, Germany, Revenue ($m), 2006-2011
Table 20: Wound-healing Therapeutics Market, Germany, Revenue ($m), 2006-2011
Table 21: Diabetic Foot Infection Therapeutics Market, Germany, Forecast ($m), 2011-2019
Table 22: Wound-healing Therapeutics Market, Germany, Forecast ($m), 2011-2019
Table 23: Diabetic Foot Infection Therapeutics Market, Italy, Revenue ($m), 2006-2011
Table 24: Wound-healing Therapeutics Market, Italy, Revenue ($m), 2006-2011
Table 25: Diabetic Foot Infection Therapeutics Market, Italy, Forecast ($m), 2011-2019
Table 26: Wound-healing Therapeutics Market, Italy, Forecast ($m), 2011-2019
Table 27: Diabetic Foot Infection Therapeutics Market, Spain, Revenue ($m), 2006-2011
Table 28: Wound-healing Therapeutics Market, Spain, Revenue ($m), 2006-2011
Table 29: Diabetic Foot Infection Therapeutics Market, Spain, Forecast ($m), 2011-2019
Table 30: Wound-healing Therapeutics Market, Spain, Forecast ($m), 2011-2019
Table 31: Diabetic Foot Infection Therapeutics Market, The UK, Revenue ($m), 2006-2011
Table 32: Wound-healing Therapeutics Market, The UK, Revenue ($m), 2006-2011
Table 33: Diabetic Foot Infection Therapeutics Market, The UK, Forecast ($m), 2011-2019
Table 34: Wound-healing Therapeutics Market, The UK, Forecast ($m), 2011-2019
Table 35: Diabetic Foot Infection Therapeutics Market, Japan, Revenue ($m), 2006-2011
Table 36: Wound-healing Therapeutics Market, Japan, Revenue ($m), 2006-2011
Table 37: Diabetic Foot Infection Therapeutics Market, Japan, Forecast ($m), 2011-2019
Table 38: Wound-healing Therapeutics Market, Japan, Forecast ($m), 2011-2019
Table 39: Diabetic Foot Ulcer Therapeutics - Phase III Pipeline, 2012
Table 40: Diabetic Foot Ulcer Therapeutics - Phase II Pipeline, 2012
Table 41: Diabetic Foot Ulcer Therapeutics - Phase I Pipeline, 2012
Table 42: Diabetic Foot Ulcer Therapeutics - Preclinical and Discovery Pipeline, 2012
Table 43: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials, 2012
Table 44: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials by Phase, 2012
Table 45: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials by Status of Development, 2012
Table 46: Diabetic Foot Ulcer Therapeutics, Global, Overall Sponsors, 2012
Table 47: Diabetic Foot Ulcer Therapeutics, Global, Prominent Sponsors, 2012
Table 48: Diabetic Foot Ulcer Therapeutics, Global, Top Ten Companies by Phase, 2012
Table 49: Pfizer, Inc. - Diabetic Foot Ulcer Pipeline Products, 2012
Table 50: Cardiovascular Biotherapeutics, Inc. - DFU Pipeline Products, 2012
Table 51: HealOr Ltd. - DFU Pipeline Products, 2012
Table 52: MacroCure Ltd. - DFU Pipeline Products, 2012
Table 53: Diabetic Foot Ulcer Therapeutics - Other Companies in the Pipeline, 2012
Table 54: Diabetic Foot Ulcer Therapeutics, Licensing and Partnership Deals, 2012

1.2 List of Figures
Figure 1: The University of Texas - Diabetic Wound Classification System
Figure 2: Diabetic Foot Ulcer - Pathophysiology
Figure 3: Diabetic Foot Infections - Antibiotic Use According to Clinical Severity
Figure 4: Diabetic Foot Ulcer - Referral Pathway
Figure 5: Diabetic Foot Infection Therapeutics Market, Global, Revenue ($m), 2006-2011
Figure 6: Wound-healing Therapeutics Market, Global, Revenue ($m), 2006-2011
Figure 7: Diabetic Foot Infection Therapeutics Market, Global, Forecast ($m), 2011-2019
Figure 8: Wound-healing Therapeutics Market, Global, Forecast ($m), 2011-2019
Figure 9: Diabetic Foot Infection Therapeutics Market, The US, Revenue ($m), 2006-2011
Figure 10: Wound-healing Therapeutics Market, The US, Revenue ($m), 2006-2011
Figure 11: Diabetic Foot Infection Therapeutics Market, The US, Forecast ($m), 2011-2019
Figure 12: Wound-healing Therapeutics Market, The US, Forecast ($m), 2011-2019
Figure 13: Diabetic Foot Infection Therapeutics Market, France, Revenue ($m), 2006-2011
Figure 14: Wound-healing Therapeutics Market, France, Revenue ($m), 2006-2011
Figure 15: Diabetic Foot Infection Therapeutics Market, France, Forecast ($m), 2011-2019
Figure 16: Wound-healing Therapeutics Market, France, Forecast ($m), 2011-2019
Figure 17: Diabetic Foot Infection Therapeutics Market, Germany, Revenue ($m), 2006-2011
Figure 18: Wound-healing Therapeutics Market, Germany, Revenue ($m), 2006-2011
Figure 19: Diabetic Foot Infection Therapeutics Market, Germany, Forecast ($m), 2011-2019
Figure 20: Wound-healing Therapeutics Market, Germany, Forecast ($m), 2011-2019
Figure 21: Diabetic Foot Infection Therapeutics Market, Italy, Revenue ($m), 2006-2011
Figure 22: Wound-healing Therapeutics Market, Italy, Revenue ($m), 2006-2011
Figure 23: Diabetic Foot Infection Therapeutics Market, Italy, Forecast ($m), 2011-2019
Figure 24: Wound-healing Therapeutics Market, Italy, Forecast ($m), 2011-2019
Figure 25: Diabetic Foot Infection Therapeutics Market, Spain, Revenue ($m), 2006-2011
Figure 26: Wound-healing Therapeutics Market, Spain, Revenue ($m), 2006-2011
Figure 27: Diabetic Foot Infection Therapeutics Market, Spain, Forecast ($m), 2011-2019
Figure 28: Wound-healing Therapeutics Market, Spain, Forecast ($m), 2011-2019
Figure 29: Diabetic Foot Infection Therapeutics Market, The UK, Revenue ($m), 2006-2011
Figure 30: Wound-healing Therapeutics Market, The UK, Revenue ($m), 2006-2011
Figure 31: Diabetic Foot Infection Therapeutics Market, The UK, Forecast ($m), 2011-2019
Figure 32: Wound-healing Therapeutics Market, The UK, Forecast ($m), 2011-2019
Figure 33: Diabetic Foot Infection Therapeutics Market, Japan, Revenue ($m), 2006-2011
Figure 34: Wound-healing Therapeutics Market, Japan, Revenue ($m), 2006-2011
Figure 35: Diabetic Foot Infection Therapeutics Market, Japan, Forecast ($m), 2011-2019
Figure 36: Wound-healing Therapeutics Market, Japan, Forecast ($m), 2011-2019
Figure 37: Diabetic Foot Ulcer Therapeutics Market, Drivers and Barriers, 2012
Figure 38: Opportunity and Unmet Need in Diabetic Foot Infection Therapeutics Market, 2012
Figure 39: Opportunity and Unmet Need in the Diabetic Foot Ulcer Wound-healing Therapeutics Market, 2012
Figure 40: Strategic Competitor Assessment of the Marketed Products in Diabetic Foot Ulcer Therapeutics, 2012
Figure 41: Diabetic Foot Ulcer Therapeutics, Clinical Pipeline by Mechanism of Action (%), 2012
Figure 42: Diabetic Foot Ulcer Therapeutics, Clinical Pipeline by Phase of Development (%), 2012
Figure 43: Technology Trends Analytics Framework, 2012
Figure 44: Technology Trends Analytics Framework - Description, 2012
Figure 45: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials by Country, 2012
Figure 46: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials by Phase (%), 2012
Figure 47: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials by Status of Development (%), 2012
Figure 48: Diabetic Foot Ulcer Therapeutics, Global, Overall Sponsors (%), 2012
Figure 49: Diabetic Foot Ulcer Therapeutics, Global, Prominent Sponsors (%), 2012
Figure 50: Diabetic Foot Ulcer Therapeutics, Global, Top Companies by Phase, 2012
Figure 51: Diabetic Foot Ulcer Therapeutics Market, Impact Analysis, 2012
Figure 52: Implications for Future Market Competition in the Diabetic Foot Ulcer Therapeutics Market, 2012
Figure 53: Diabetic Foot Ulcer Therapeutics, Clinical Pipeline by Company, 2012
Figure 54: GlobalData Market Size Estimation
Figure 55: GlobalData Market Forecasting Model

Diabetic Foot Ulcer Therapeutics Market Relying on Pipeline Therapies for Growth

The Diabetic Foot Ulcers (DFU) therapeutics market faces a turbulent few years as drug patents expire and new therapies appear on the scene, says a new report by pharmaceutical industry analysts GlobalData.

The report* outlines the problems facing the DFU therapeutics industry, including drug genericization, problematic treatments and corresponding negative public opinion.

The DFU therapeutics market, made up of the Diabetic Foot Infection (DFI) and wound healing sectors, grew from a value of $1.13 billion in 2006, to $1.53 billion in 2011. During this period the DFI portion climbed from $1 billion to $1.46 billion, but the wound healing segment had a very different fate.

The wound healing therapeutics market consists of just one product – Regranex. In 2008, the US Food and Drugs Administration (FDA) slapped a ‘black box’ warning on the product due to concerns that large quantities could increase the risk of cancer by up to five times. The US public responded with their feet, generally avoiding the medication. Accordingly, the wound healing market dropped from $126.5m in 2006, to $73.8m in 2011, dropping at a negative Compound Annual Growth Rate (CAGR) of 10.2%.

The DFI sector was also not without its woes. The three major drugs in this area all have side effect issues: Zyvox has been reported to cause myelosuppression, hematological adverse events, and optic neuropathy, whereas Invanz and Zosyn are associated with hypersensitivity reactions, and Invanz has the potential to cause seizures.

However, problems with these current treatments means there are opportunities for new drugs to push through and make an impression on the market.

The DFU therapeutics pipeline is made up of 40 molecules, 29 of which can boast first-in-class status. In the wound healing sector, the controversial Regranex is expected to be replaced by treatments such as Fragmin, Trafermin and CVBT141B. In contrast, the DFI sector will be affected by the patent expiration of Zyvox and Invanz in 2015 and 2016, respectively. This will prompt a rise in generic alternatives.

Considering these differing fortunes, GlobalData expects the DFU therapeutics market to show moderate growth, climbing from $1.53 billion in 2011 to reach $1.97 billion in 2019.

* Diabetic Foot Ulcer Therapeutics - Pipeline Assessment and Market Forecasts to 2019

This report is an essential source of information and analysis on the global Diabetic Foot Ulcers Therapeutics market. It also identifies the key trends shaping and driving the global Diabetic Foot Ulcers Therapeutics market.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.

Pfizer Inc.
Cardiovascular Biotherapeutics, Inc.
HealOr Ltd.
MacroCure Ltd.